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Tuberculosis in migrants – screening,
surveillance and ethics
Gabriella Scandurra1*, Chris Degeling2, Paul Douglas3, Claudia C. Dobler4 and Ben Marais1
Abstract
Tuberculosis (TB) is the leading infectious cause of human mortality and is responsible for nearly 2 million deaths
every year. It is often regarded as a ‘silent killer’ because it predominantly affects the poor and marginalized, and
disease outbreaks occur in ‘slow motion’ compared to Ebola or coronavirus 2 (COVID-19). In low incidence
countries, TB is predominantly an imported disease and TB control in migrants is pivotal for countries to progress
towards TB elimination in accordance with the World Health Organisations (WHO’s) End TB strategy. This review
provides a brief overview of the different screening approaches and surveillance processes that are in place in low
TB incidence countries. It also includes a detailed discussion of the ethical issues related to TB screening of migrants
in these settings and the different interests that need to be balanced. Given recognition that a holistic approach
that recognizes and respects basic human rights is required to end TB, the review considers the complexities that
require consideration in low-incidence countries that are aiming for TB elimination.
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Introduction
Tuberculosis (TB), is one of the oldest airborne patho-
gens; found in human remains from nearly 10,000 years
ago [1]. Despite its ancient history, TB remains the
number one infectious disease killer on the planet
(WHO report) with an estimated 10 million people de-
veloping TB every year, resulting in nearly 2 million
deaths [2]. TB disproportionally affects socioeconomi-
cally disadvantaged populations living in low-and
middle-income countries in Asia and Africa and is
often referred to as the “silent epidemic”, because of its
relatively slow spread and the fact that affected popula-
tions are often ‘less visible’. Mycobacterium tubercu-
losis, the causative organism of TB disease, is
approximately 50 times slower to grow than other com-
mon bacteria, and TB disease develops more slowly
than high profile viral epidemics such as Ebola or cor-
onavirus 2 (COVID-19). Because TB mainly affects
socioeconomically disadvantaged groups [3] (whose
voice is often not heard) and appears less threatening
to high-income countries than other pandemics, re-
search progress on TB diagnostics and treatments has
been slow.
Galvanized by the World Health Organization’s STOP
TB and END TB campaigns [4, 5], active case finding
initiatives have successfully reduced the prevalence of
TB [6, 7] and randomized control trials are informing
better ways to find and treat TB cases [8, 9]. The im-
portance of new tools, and better ways of finding and
treating all people with TB are well recognized, as is the
need to address the many social, financial, ethical, and
cultural barriers that limit access to TB prevention, diag-
nosis and care [2]. But progress requires high level polit-
ical commitment and sufficient financial resources to
implement solutions that have been shown to work. A
holistic approach is essential to effectively tackle the
many challenges posed by global TB control [10], in-
cluding careful consideration of TB in migrants. Here
we focus on the practice and ethics of TB screening and
surveillance in migrants.
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A world in motion
Globalization while traditionally focused on trade and fi-
nance has become one of the driving factors of people
movement around the world. Improvements in transpor-
tation technology, decrease in travel time and costs have
been integral in changing the patterns of migration in
the world today with 3.4% of the world’s population res-
iding in a country other than their county of birth
(IOM). Global mobility and connectivity supports
growth in international trade, exchange of ideas, new
technology and social/cultural interaction, but it also in-
creases the risk of infectious disease spread and global
pandemics, as illustrated by the current severe acute re-
spiratory syndrome COVID-19 outbreak.
Transmission sustains the epidemic
The global TB epidemic, declared by WHO as a global
health emergency in 1993, is driven by ongoing trans-
mission [11] and factors increasing population vulner-
ability [12], which also applies to emerging drug
resistant disease [13–15]. Modelling suggests that ado-
lescents and young adults are major drivers of TB trans-
mission in high incidence countries [16] . During the
period 2000–2017, the total number of international mi-
grants rose from 173 million to 258 million, an increase
of 49% [17].
Of the infected people who develop TB disease, the
majority will become ill within 2–5 years from their
most recent infection, but in some people TB disease
may be many years after the last infection episode [18].
In low TB incidence countries where TB transmission is
limited and most latent TB infection [LTBI] (as well as
active disease) is imported from high incidence settings
[19], preventing re-activation of LTBI is a major TB con-
trol strategy in migrant populations [20, 21]. However,
given the high mobility and circulatory nature of mi-
grant populations and the fact that the organism moves
with people and crosses national borders with ease [22,
23], future re-infection when visiting areas of the world
with poor epidemic control where most TB and drug re-
sistant TB (DR-TB) transmission occurs [11], remains a
concern.
Active TB screening
TB screening policies for migrants attempt to protect
populations in low incidence countries against imported
TB disease and these mainly focus on pre-migration
screening of migrants prior to obtaining travel approval,
as implemented by Australia, Canada, New Zealand
(NZ), the United Kingdom (UK) and the United States
of America (US) [24], as well as the Gulf Corporation
Countries (GCC) or post-migration screening after mi-
grants arrive in their destination country, which is pre-
dominantly the European approach [25]. A systematic
review that analysed TB screening policies in 15 coun-
tries, demonstrated poor consistency of practice and
standardization [26], stemming from the distinct geog-
raphies of each receiving country and different migrant
entry routes. Variation in TB screening practices among
migrants also reflects the lack of evidence to guide the
most effective, efficient and cost-effective TB screening
approaches.
Variation in national policies and practices for TB
screening in migrants mainly relate to differences in risk
factor assessment and different risk thresholds based on
the estimated TB incidence in the country of origin [27,
28]. Discrepancies include the definition of a “high TB
burden country” (ranging from 40, 60 or 100 per 100,
000 population) [27, 29], the intended period of stay
(usually greater than 3 or 6 months) and the visa cat-
egory that triggers formal TB screening and post-arrival
surveillance of migrants deemed at high risk of develop-
ing TB identified during initial screening. People on
refugee or humanitarian visa subclasses have often been
considered as high-risk groups [28, 30], but their TB risk
is highly variable and dependent on the specific refugee
cohort (e.g. based on the TB incidence in the country of
origin). Practices differ with some countries in Europe
(like Greece and Spain) screening all asylum seekers and
others (like Italy) not having any formal screening of
asylum seekers [31]. Countries like Australia, screen all
persons entering on humanitarian visas (which are a per-
manent visa category) and when determining the TB risk
posed by temporary migrants in Australia, great em-
phasis is placed on the estimated TB incidence in the
country of origin and their declared length of stay [32].
There are many barriers to TB screening, detection
and treatment among asylum seekers and refugees, one
being stigma, and these will be further discussed in the
ethics section of this review. Only through data sharing
and research will we acquire better evidence to guide
optimal TB screening methods in migrants. Access to
essential health services by refugees and migrants vary
by country [33] and are determined by national law. Im-
plementation of the improvements to migrant and refu-
gee health, must take account of specific country
situations and be in accordance with national legislation,
priorities and circumstances, and international instru-
ments on equal access to public health care services.
TB surveillance and monitoring
Electronic TB databases, such as E-detect in Europe [34]
and eMedical in Australia [35] have been established for
the better surveillance and epidemiological analysis to
inform future TB control interventions [36]. E-detect
arose from a tuberculosis consortium, shared by 6 Euro-
pean Union countries, Sweeden, Netherlands, UK, Italy,
Romaina and Bulgaria, bringing together world leading
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TB experts in national public health agencies with indus-
try and major academic centres to address the high dis-
ease burden of TB and multi-drug resistant TB through
evidenced-based interventions, in vulnerable EU popula-
tions, including migrants [37]. E-detect is geared towards
TB diagnosis and detection among new and settled asy-
lum seekers and refugees and, importantly, linking pa-
tients into the health care system once they have been
diagnosed. E-detect also provides standardized TB data
from partner countries, including data on LTBI, with the
goal of enhancing intercountry collaboration to support
the implementation of future TB screening policies and
frameworks. Participating countries collect, clean and re-
code data using a unique de-identified identifier on a
range of TB screening data fields (country of screening,
screening scheme, sex, age, country of origin, screening
performed, screening results and where available, data
on initiated and completed treatment), which is then
uploaded to the shared database [34]. This allows ana-
lysis of best practice from countries where national stra-
tegic plans have been most effective, aiding the
development of shared and optimised frameworks for
enhanced TB control.
E-detect can also be linked with the E-Detect TB
smartphone App to assist active case finding among
contacts and detect co-prevalent cases [38]. Rapid
‘digital screening’ via a mobile device supports the rapid
identification and testing of those individuals who re-
quire prioritization for sputum collection and Xpert
Ultra® testing. Use of this system have been shown to as-
sist earlier diagnosis and the direct transfer of relevant
patient information to referral hospitals in Italy, improv-
ing the overall cascade of care in vulnerable and margin-
alized migrant communities [38].
In Australia, the eMedical database of the Department
of Home Affairs collects all TB health information of
migrating individuals from the health screening process
conducted pre- or post-migration [35]. The database has
particular value to identify migrants at high risk of de-
veloping TB post-arrival, for example if a lung lesion
consistent with TB is detected during initial chest radi-
ography screening, but without microbiological proof of
active TB disease. These migrants will undergo ongoing
surveillance for disease development or receive prevent-
ive TB treatment post-arrival once active disease has
been ruled out [39]. Migrants at high risk of developing
TB enter into a legally binding agreement as a specific
condition of a visa to comply with TB surveillance con-
ducted by local TB health services, referred to as a ‘TB
undertaking’. Similarly, electronic databases used by
Canada, NZ, and the US, collect information including
country of origin, date of birth, gender, occupation, visa
details, health data including self-declaration on TB
symptoms, previous TB contact, results of chest
radiographs, diagnostic test results from sputum smear
or culture, treatment regimens and medical follow-up
from migrants. This information is vital for TB control
with the goal to eventually eliminate TB [21, 40, 41].
Whole genome sequencing (WGS) provides excellent
M. tuberculosis strain resolution in order to differentiate
imported from locally transmitted strains and strain
clusters [42–46]. Australia’s most populous state New
South Wales implemented routine WGS of all culture-
confirmed TB cases in 2016, which guided better tar-
geted public health responses and confirmed that local
transmission is limited [12, 47, 48]. WGS provides valu-
able information to assist individual patient management
and public health responses, but widespread implemen-
tation in resource-limited settings remains unrealistic at
present. Enhanced polymerase chain reaction (PCR)
based methods may be more feasible in the interim, both
for genetic drug resistance determination and transmis-
sion tracking [49]. In time, the establishment of global
TB surveillance systems will complement epidemio-
logical surveillance and could track cross-border trans-
mission dynamics, but also pose risks to personal
freedom that should be considered (see Ethics section).
LTBI screening
Acknowledging that LTBI provides a reservoir of infec-
tion from which future TB cases may arise [50], low-
incidence countries have increasingly implemented LTBI
screening among migrants, either pre-departure or post
arrival [24, 51]. According to a survey of policies in 29
Organisation for Economic Cooperation and Develop-
ment (OECD) countries, 16 countries (55%) routinely
screened migrants for LTBI [52]. Target populations for
LTBI screening vary by age and the country of origin.
Australia, and the US only screen migrant children (aged
up to 10 years for Australia and up to 15 years for US)
for LTBI, as a marker of possible TB disease that justifies
a chest radiograph if positive. Testing for LTBI is done
using a traditional tuberculin skin test (TST) or an
interferon-gamma release assay (IGRA), which has
higher specificity.
In a Taiwanese study, the highest number of TB cases
found among migrants were identified less than 2 years
after migration in individuals who had a clear chest
radiograph at initial TB screening [53]. In other settings,
the documented risk of LTBI reactivation is elevated in
migrants who have fibrotic scars ≥2 × 2 cm and/or calci-
fied nodules ≥1.5 mm on chest radiograph consistent
with previous TB infection [24, 54, 55]. An Australian
study found that 1.3% of migrants (428/32,550 migrants)
deemed to be at a high risk of developing TB based on
pre-migration screening (mainly because of chest radio-
graph abnormalities) developed TB [39]. Of these TB
cases, 270 (63%) were diagnosed during active TB
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follow-up in the first 2 years post migration; the period
of their ‘TB undertaking’.
Treating high risk migrants for LTBI, once TB disease
has been ruled out, should benefit individual migrants
and the general public [56], although formal cost effect-
iveness analyses remain limited. A systematic review of
16 studies on LTBI screening among migrants did not
arrive at any definite conclusions about the (cost-) ef-
fectiveness of this intervention [57]. The (cost-) effect-
iveness of LTBI screening and treatment among
migrants was limited by the high number of migrants
lost at some level of the care cascade and the fact that
only a small number completed LTBI treatment. A mod-
elling study showed that pre-migration screening using
an IGRA combined with post-arrival treatment with 4
months of rifampicin among migrants from countries
with moderate to high TB incidence resulted in the best
cost-effectiveness ratios [58].
With increased global mobility, a growing number of
short-term migrants enter low TB incidence countries
repeatedly without TB screening, because their intended
period of stay is less than the specified cut-off triggering
such a requirement. It is unclear to what extent these
temporary migrants might contribute to TB disease im-
portation, but the benefits of screening and treating
these migrants for LTBI would likely be diminished by
ongoing TB exposure in their countries of origin. The le-
gitimacy of pre-migration TB screening has been ques-
tioned, [59, 60] with some arguing that better primary
care should be available for migrants to support their
general health and wellbeing, as well as early TB identifi-
cation. Patient-centered approaches to TB care have
been shown to reduce diagnostic delay, with likely re-
duction in TB transmission, and improve treatment
outcome in migrants [61]. We explore some of the ten-
sions between the classic public health and social dimen-
sions of the problem, as well as the resultant ethical
dilemmas in greater detail.
Ethical dimensions
The TB status of migrants has normative dimensions be-
cause of the potential health impacts to individuals and
others, and the associated limitations a positive diagnosis
can have on their movements within and between coun-
tries. Ethical issues related to migrant TB screening are
briefly discussed and summarised in Table 1. TB screen-
ing of migrants should mainly be justified on the basis of
providing appropriate medical care [62]. Being diagnosed
with TB or LTBI can serve as a point of discrimination,
which can impinge upon the opportunities and choices
available to individuals, and increase the risk of harms
through TB-related health inequities and social stigma.
Current conceptualizations of stigma identify two basic
forms [63]. ‘Enacted TB stigma’ refers to exclusion, re-
jection or devaluation by others based on beliefs of social
unacceptability. ‘Perceived TB stigma’ refers to patient
and family fears of inferiority stemming from the antici-
pation of an adverse judgment related to a TB diagnosis.
Both cause harms to individuals and groups and are rec-
ognized to be a significant barrier to health care
utilization and adherence to TB treatment [64, 65]. Con-
sequently, as is the case with all other TB patients, the
privacy and confidentiality of migrants using TB services
needs to be protected at all times [62].
Unfortunately, historical TB control efforts frequently
entwined immigration and public health law, which ex-
acerbated stigma and xenophobia and requires constant
vigilance [66, 67]. Under these conditions TB screening
Table 1 Overview of ethical issues related to migrant TB screening
Issues identified Key considerations
Care obligation linked to TB screening The human rights issue of providing appropriate medical care to all people, irrelevant of TB or LTBI
Stigma
Enacted TB stigma Exclusion, rejection or devaluation by others based on beliefs of inferiority or social unacceptability
Perceived TB stigma Patient and family fears of inferiority stemming from the anticipation of an adverse judgment
related to a TB diagnosis
“At-risk group” stigma Magnify a migrants sense of being “out of place”. This requires careful attention to appropriate
service design and communication strategies. How best to communicate with migrants to inform
them about the potential benefits and risks of TB and LTBI screening requires more research.
Privacy and confidentiality Needs to be respected and protected at all times
Racial vilification Irresponsible media reporting of TB in migrants is implicated in the production of stigma and
should be avoided; and racial vilification banned/censored on social media
Health equity All migrants (whether they have TB or otherwise) should have access to basic health services
that are both medically and culturally appropriate.
Trust in the health care system/provider Migrants come from countries with weak health systems and often mistrust health systems.
Building trust is essential to build constructive and respectful relationships between service
providers and migrant communities.
LTBI Latent tuberculosis infection, TB Tuberculosis
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is not politically benign, but has broad consequences for
those being targeted to participate. Concerns about the
public health aspects of migration processes increasing
the risk of racial vilification are not insignificant, as sev-
eral studies suggest that TB control measures and repre-
sentations of migrants in the media as agents of disease
may exacerbate stigma [68]. A systematic review of
qualitative studies indicates feelings of stigmatization de-
rived from being labelled as a member of an “at-risk
group” for TB by health services in their new country of
residence, can further magnify migrants sense of being
“out of place” [69].
Little research has focused on the specific experience
of new migrants, nor sought their views on the best ways
forward. For those organizing TB programmes and mi-
gration processes, key decisions need to be made as to
the most appropriate setting for migration related TB
screening and how best to communicate with migrant
groups about the potential benefits and risks of these ac-
tivities [70]. Whether TB screening is conducted pre-
migration, as a mandatory part of standard immigration
processes, or provided as a non-mandated service, before
or after arrival in the new country, distributes the bur-
dens of testing and TB diagnosis differently. Respect for
human rights means that participation in health screen-
ing should be voluntary – to the extent that competent
individuals should always be acting autonomously on the
basis of their informed preferences. Nevertheless, some
forms of coercion can be ethically justified if they pro-
mote significant benefits for the wider population [71,
72]. Because earlier TB case identification will reduce
the future population burden of TB disease, screening
that is linked to entry or legalizing residence can achieve
this aim by potentially identifying and treating immi-
grants with TB at the earliest time point to prevent
transmission within the recipient/host country. How-
ever, the use of these mechanisms to enforce participa-
tion and potentially transfer screening costs should be
carefully considered to minimize harm and creates re-
sponsibilities for immigration authorities.
Because access to health care in countries of origin
may be limited, it can be challenging for immigration
authorities to meet migrants’ health needs if pre-
migration treatment is required. Coercion in the context
of TB screening can also be counter-productive if it is
not accompanied by clear communication about the im-
plications of the diagnosis, the disease or the LTBI de-
tection [73] People will ignore or doubt the importance
and purpose of TB screening if the reasons they are
given for participation are at odds with their worldviews,
values, or both [74]. Poor communication and a failure
to accommodate the values of those being targeted can
lead to non-compliance and subsequent treatment fail-
ure. When treatment is undertaken in the recipient/host
country, uncertainty about an individual’s legal status
may exacerbate problems of health care access [65].
Challenges faced by migrants such as communication
problems, loss of social support, discrimination and ac-
culturation can be aggravated by stigma and other socio-
cultural impacts of a positive TB diagnosis [75]. Never-
theless, because of health equity, social justice and public
health concerns, it is important that all migrants
(whether they have TB or otherwise) have access to basic
health services that are both medically and culturally ap-
propriate [76, 77].
As outlined above, the implementation of TB screen-
ing often results in conflicting interests and creates a
tension between the obligation of the state to protect the
health of the public on one hand, and respecting the au-
tonomy, health interests, and liberty of the screened in-
dividuals on the other. Screening also creates obligations
on the screener to ensure that participants are properly
supported and have pathways to address detected abnor-
malities [78]. Screening should only be undertaken with
the intention to treat and with an appropriate level of
counselling ahead of such screening. The principle of
reciprocity is important to guide the inclusion of certain
‘migrant rights’ into screening guidelines. Screening cre-
ates a two-way obligation, upon migrants to actively par-
ticipate in the programme, and upon authorities to
reciprocate the migrants’ participation and the benefits
for the control of public health [79].
In considering these background conditions, trust is
an important requirement for appropriate service design
and delivery for TB screening. Trust is also central to ef-
fective communication because it can initiate or build
constructive and respectful relationships between service
providers and migrant communities. Migrants often
come from countries with weak health systems so may
not trust providers or be encultured to seek professional
health advice [65]. To engender trustworthiness, there is
a need for clarity from service providers as to whom any
migration-related screening programme is designed to
benefit and the rationale underpinning decisions about
how resulting burdens are distributed [78]. When con-
sidering the benefits and burdens of TB screening, the
potential for stigma must be a key concern. TB stigma
commonly arises from public health responses to TB in
ways that influence affected populations as well as rele-
vant institutions [80–83]. This is not to say that manifes-
tations of stigma are inevitable; careful attention to
appropriate service design and communication strategies
can work to mitigate these impacts and risks [74]. Sys-
tematic evaluations indicate that the optimum approach
in high-migrant receiving countries is to offer screening
in a range of settings, incorporating a strong focus on
community engagement and partnership with migrant
organisations in both the design and implementation of
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screening approaches [65, 75]. Such programmes should
ensure that access to diagnostics and treatment are free
of charge to maximise access and adherence.
Conclusion
Aiming for TB elimination in countries where TB is es-
sentially an imported disease requires careful consider-
ation of migrant populations’ best interests and what a
holistic TB response should look like. Particular areas
requiring better evidence-based solutions include 1) ob-
jective and pragmatic risk stratification approaches, 2)
better screening and diagnostic tools, and 3) optimal
management of LTBI in situations where disease risk is
low or the risk of future re-infection high [84, 85]. Given
near-total travel bans implemented in the wake of the
COVID-19 epidemic, it is an opportune time to critically
reconsider and refine migration policies as borders begin
to re-open.
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